Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

90.57 +0.93 (+1.04%)
Streaming Delayed Price Updated: 1:23 PM EDT, Sep 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Axsome Thera

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Axsome Therapeutics, Inc. (AXSM) Q1 2021 Earnings Call Transcript
AXSM earnings call for the period ending March 31, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
2 Top Biotech Stocks to Buy Right Now
The stocks of Novavax and Axsome Therapeutics are soaring. Here's why. 
Via The Motley Fool
Exposures COVID-19
3 Biotech Stocks That Could Be Millionaire-Makers
Their stocks have collapsed. But they could still be huge winners. 
Via The Motley Fool
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving Today
Voyager Therapeutics, Inc. (NASDAQ: VYGR), uniQure N.V. (NASDAQ: QURE), Axsome Therapeutics, Inc. (NASDAQ: AXSM), Reviva Pharmaceuticals Holdings, Inc. (NASDAQ:RVPH) and CRISPR... 
Via Benzinga
Why Axsome Therapeutics Stock Is Jumping Today
The FDA granted Priority Review to the biotech's regulatory filing for its lead pipeline candidate. 
Via The Motley Fool
Exposures Product Safety
Thinking About Buying Stock In Immunome, Axsome Or Etsy?
Immunome Inc (NASDAQ:IMNM) shares are trading higher by 9.25% by $32.28 after the ... 
Via Benzinga
The Week Ahead In Biotech (May 9-15): Heron, Apellis FDA Decisions, Presentations and Earnings
Biotech stocks came under pressure in the week ended May 7 as traders digested a slew of earnings news flow and a handful of clinical trial readouts. COVID-19 vaccine stocks came... 
Via Benzinga
Exposures COVID-19 Product Safety
58 Biggest Movers From Yesterday
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial... 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) surged 46.9% to $6.25 after the company announced the full details of its Phase 2 trial evaluating its lead drug... 
Via Benzinga
FDA Begins Priority Review of Axsome Therapeutics' Potential New Depression Drug
The first new treatment for millions of Americans with major depressive disorder could become available this summer. 
Via The Motley Fool
Exposures Product Safety
Axsome Stock Jumps After Snagging Priority Review For Depression Drug
Axsome Therapeutics snagged a speedy review from the FDA for its depression treatment on Monday, leading Axsome stock to gap higher. 
Via Investor's Business Daily
Exposures Product Safety
AXSM Stock: The Big FDA News Giving Axsome Therapeutics a Boost
AXSM stock is gaining on Monday after the FDA granted its new drug application priority review. Here's what you should know now. 
Via InvestorPlace
Exposures Product Safety
12 Health Care Stocks Moving In Monday's Pre-Market Session
Gainers Ocugen (NASDAQ:OCGN) shares rose 13.81% to $10.96 during Monday's pre-market session. The market value of their outstanding shares is at $2.0 billion. Advaxis... 
Via Benzinga
Axsome Therapeutics Stock Jumps As FDA Accepts AXS-05 Application In Major Depressive Disorder
Under Priority review status, the FDA has accepted Axsome Therapeutics Inc's (NASDAQ: AXSM) marketing application for AXS-05 for major depressive disorder (MDD... 
Via Benzinga
Exposures Product Safety
Alzheimer's Disease: 5 Stocks on Biotech Radars
What's been interesting for the past couple of years, and especially the last few months, is to watch the rise of emerging, small-cap Biotech companies trying to take on the big AD and other... 
Via Talk Markets
The Daily Biotech Pulse: KemPharm Receives $10M Milestone Payment, Zymergen, Neuropace Debut On Nasdaq, Renalytix Wins US Government Contract, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 21) Alexion Pharmaceuticals,... 
Via Benzinga
Stocks That Hit 52-Week Lows On Wednesday
Wednesday morning, 25 companies reached new 52-week lows. Intriguing Points: Lufax Holding (NYSE:LU) was the biggest company by market cap to set a new 52-week low... 
Via Benzinga
The Daily Biotech Pulse: Moderna To Supply Variant-Specific Vaccine To Israel, Roche's Diagnostics Business Comes to Rescue
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 20) Alexion Pharmaceuticals,... 
Via Benzinga
The Daily Biotech Pulse: Novavax CFO Departs, Zai Lab Inks Cancer Drug Collaboration, FDA Nod For Gilead
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 13) Bio-Techne Corporation (... 
Via Benzinga
Exposures Product Safety
Stocks That Hit 52-Week Lows On Monday
Before 10 a.m. ET on Monday, 30 stocks hit new 52-week lows. Interesting Highlights: The largest company by market cap to set a new 52-week low was Ionis Pharmaceuticals (... 
Via Benzinga
The Daily Biotech Pulse: Leadership Transition At Amarin, Vaccine Setback For J&J, FDA Nod For Label Expansion of Roche's Asthma Drug
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 12) 180 Life Sciences Corp. (... 
Via Benzinga
Exposures Product Safety
The Daily Biotech Pulse: Negative Regulatory Tidings For Provention Bio, Celcuity Soars On In-licensing Deal, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 8) Aclaris Therapeutics, Inc... 
Via Benzinga
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.